[go: up one dir, main page]

WO2016061320A3 - Timber therapy for post-traumatic stress disorder - Google Patents

Timber therapy for post-traumatic stress disorder Download PDF

Info

Publication number
WO2016061320A3
WO2016061320A3 PCT/US2015/055687 US2015055687W WO2016061320A3 WO 2016061320 A3 WO2016061320 A3 WO 2016061320A3 US 2015055687 W US2015055687 W US 2015055687W WO 2016061320 A3 WO2016061320 A3 WO 2016061320A3
Authority
WO
WIPO (PCT)
Prior art keywords
timber
therapy
post
stress disorder
traumatic stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/055687
Other languages
French (fr)
Other versions
WO2016061320A2 (en
Inventor
Basant K. PRADHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rowan University
Original Assignee
Rowan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rowan University filed Critical Rowan University
Publication of WO2016061320A2 publication Critical patent/WO2016061320A2/en
Publication of WO2016061320A3 publication Critical patent/WO2016061320A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A61B5/163—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state by tracking eye movement, gaze, or pupil change
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/486—Biofeedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/004—Magnetotherapy specially adapted for a specific therapy
    • A61N2/006—Magnetotherapy specially adapted for a specific therapy for magnetic stimulation of nerve tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Educational Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Social Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The disclosure relates to a therapeutic method based on TIMBER (Trauma Interventions using Mindfulness Based Extinction and/or Reconsolidation). TIMBER is a psychotherapy protocol that consists of 2 parts: a brief version (mini-TIMBER) and an elaborate version (full-TIMBER).
PCT/US2015/055687 2014-10-15 2015-10-15 Timber therapy for post-traumatic stress disorder Ceased WO2016061320A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064000P 2014-10-15 2014-10-15
US62/064,000 2014-10-15

Publications (2)

Publication Number Publication Date
WO2016061320A2 WO2016061320A2 (en) 2016-04-21
WO2016061320A3 true WO2016061320A3 (en) 2016-09-29

Family

ID=55747550

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/055687 Ceased WO2016061320A2 (en) 2014-10-15 2015-10-15 Timber therapy for post-traumatic stress disorder

Country Status (1)

Country Link
WO (1) WO2016061320A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018274765A1 (en) * 2017-05-25 2020-01-23 Glytech Llc. Formulations for treatment of post-traumatic stress disorder
US11848079B2 (en) * 2019-02-06 2023-12-19 Aic Innovations Group, Inc. Biomarker identification
BR112022019234A2 (en) * 2020-03-23 2022-11-08 Rustick Joseph METHOD FOR TREATMENT OF NEUROLOGICAL DISORDERS USING SYNAPTIC PATHWAY TRAINING
US20210401774A1 (en) * 2020-06-27 2021-12-30 Robert Brent Turnipseed Ketamine protocols and data evaluation for treatment-resistant depression and trauma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039468A2 (en) * 2001-11-06 2003-05-15 Haracz John L Antimnemonic therapy for hypermemory syndromes
US20090319347A1 (en) * 2006-07-12 2009-12-24 Henry Albrecht Systems and methods for a holistic well-being assessment
US20110282404A1 (en) * 2008-07-02 2011-11-17 The Board Of Regents, The University Of Texas System Methods for Enhancing Exposure Therapy Using Vagus Nerve Stimulation
US20120295852A1 (en) * 2009-10-05 2012-11-22 Joseph Moskal Methods of treating depression and other related diseases
US20130281798A1 (en) * 2012-04-23 2013-10-24 Sackett Solutions & Innovations, LLC Cognitive biometric systems to monitor emotions and stress

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039468A2 (en) * 2001-11-06 2003-05-15 Haracz John L Antimnemonic therapy for hypermemory syndromes
US20090319347A1 (en) * 2006-07-12 2009-12-24 Henry Albrecht Systems and methods for a holistic well-being assessment
US20110282404A1 (en) * 2008-07-02 2011-11-17 The Board Of Regents, The University Of Texas System Methods for Enhancing Exposure Therapy Using Vagus Nerve Stimulation
US20120295852A1 (en) * 2009-10-05 2012-11-22 Joseph Moskal Methods of treating depression and other related diseases
US20130281798A1 (en) * 2012-04-23 2013-10-24 Sackett Solutions & Innovations, LLC Cognitive biometric systems to monitor emotions and stress

Also Published As

Publication number Publication date
WO2016061320A2 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
EP3638235A4 (en) Compounds for modulating s1p1 activity and methods of using the same
AU2017261336A1 (en) Modulators of the integrated stress pathway
AU2017260367A1 (en) Modulators of the integrated stress pathway
EP3271011A4 (en) Method, system and apparatus for non-invasive neurostimulation therapy of the brain
EP3270994A4 (en) Methods and apparatus for ventilatory treatment of respiratory disorders
AU2017260374A1 (en) Modulators of the integrated stress pathway
EP3268073A4 (en) Respiratory therapy apparatus and method
EP3716997A4 (en) Methods of treatment with asparaginase
HK1255034A1 (en) Somatostatin modulators and uses thereof
EP3145562A4 (en) Apparatus and method for the preparation and administration of blood components
EP3755312A4 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
HK1255074A1 (en) Somatostatin modulators and uses thereof
EP3228085A4 (en) Display apparatus, and method of operating the display apparatus
WO2016061320A3 (en) Timber therapy for post-traumatic stress disorder
TW201613639A (en) Methods for treating cardiovascular diseases
EP3738559B8 (en) System for therapy of the eye by treating tissue using non-linear interaction
EP3565583A4 (en) Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase
EP3145567A4 (en) Device and method for administering medicaments to the brain
EP3704485A4 (en) Diagnostic and therapeutic methods for type 2 diabetes
EP3347004A4 (en) Intravenous baclofen and methods of treatment
HK40105456A (en) Treatment for modulating gut microbiota
HK40063224A (en) Treatment of respiratory disorders with arachidonate15-lipoxygenase (alox15) inhibitors
HK40067230A (en) Therapeutic methods and uses thereof
HK40072946A (en) Novel molecules for therapy and diagnosis
HK40060250A (en) Novel molecules for therapy and diagnosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15850510

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15850510

Country of ref document: EP

Kind code of ref document: A2